GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Square Pharmaceuticals PLC (DHA:SQURPHARMA) » Definitions » 5-Year Yield-on-Cost %

Square Pharmaceuticals (DHA:SQURPHARMA) 5-Year Yield-on-Cost % : 19.38 (As of May. 15, 2025)


View and export this data going back to . Start your Free Trial

What is Square Pharmaceuticals 5-Year Yield-on-Cost %?

Square Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2025 was 19.38.


The historical rank and industry rank for Square Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:

DHA:SQURPHARMA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.95   Med: 7.26   Max: 19.38
Current: 19.38


During the past 13 years, Square Pharmaceuticals's highest Yield on Cost was 19.38. The lowest was 2.95. And the median was 7.26.


DHA:SQURPHARMA's 5-Year Yield-on-Cost % is ranked better than
95.53% of 515 companies
in the Drug Manufacturers industry
Industry Median: 2.31 vs DHA:SQURPHARMA: 19.38

Competitive Comparison of Square Pharmaceuticals's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Square Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Square Pharmaceuticals's 5-Year Yield-on-Cost % falls into.


;
;

Square Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Square Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Square Pharmaceuticals  (DHA:SQURPHARMA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Square Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Square Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Square Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. Company also provides devices such as AnsuPen and AnsuPen Twist. The company operates in Bangladesh and sells its products locally and internationally.

Square Pharmaceuticals Headlines

No Headlines